Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine after incomplete revascularization following PCI in chronic angina
2011-002507-15Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis and angina pectoris comparing Ranolazine + standard medical therapy with Placebo + standard medical therapy (2 arms). Primary endpoint: Primary efficacy endpoint. Started Dec 2011; status: completed.
02
Drugs
ranolazine
03
Conditions
coronary arteriosclerosisangina pectoris
Beyond the preview
Go deeper on 2011-002507-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002507-15.